Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Randomized, Parallel-group Evaluation of LAMICTAL Extended-release Adjunctive Therapy in Subjects With Partial Seizures
Conditions
Interventions
LAMICTAL extended-release
Locations
148
United States
GSK Investigational Site
Anniston, Alabama, United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Northport, Alabama, United States
GSK Investigational Site
Tuscaloosa, Alabama, United States
GSK Investigational Site
Mesa, Arizona, United States
GSK Investigational Site
Phoenix, Arizona, United States
Start Date
October 1, 2004
Primary Completion Date
July 1, 2007
Completion Date
July 1, 2007
Last Updated
December 5, 2016
NCT02531880
NCT06097195
NCT06315322
NCT06388707
NCT06794606
NCT07505004
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions